Receive The Newest Study Notifications

National Cancer Institute (NCI) Study Designed to Investigate Zotiraciclib in Combination with Temozolomide (TMZ) Presented During Poster Session at ASCO 2019 Maximum Tolerated Dose of Zotiraciclib (250mg) Elicits Tumor Reduction, Suggesting Activity in Glioblastoma...

Brooklyn ImmunoTherapeutics, a biopharmaceutical company focused on exploring the role that cytokine-based therapy can have in treating patients with cancer, today announced the presentation of an ongoing trial poster at the 2019 American Society of Clinical Oncology...

AstraZeneca and Merck (NYSE:MRK), known as MSD outside the United States and Canada), today presented full results from the Phase 3 SOLO3 trial which evaluated LYNPARZA, compared to chemotherapy, for the treatment of platinum-sensitive relapsed patients with...

Study will evaluate safety and efficacy of Shylicine®, the first-ever investigational treatment developed for microvillus inclusion disease HAMDEN, Conn., June 4, 2019 /PRNewswire/ -- Vanessa Research, Inc. (VRI) — a biomedical company founded on the desire to "give...

DEEPER INSIGHTS Correlation of Angiogenesis Biomarkers with Early Metastatic Progression in NSCLC A study looking at 10,500 health records of advanced non-small cell lung cancer (aNSCLC) patients from ASCO’s CancerLinQ database found that the use of expanded clinical...

Ensifentrine delivery via MDI inhalers could dramatically expand clinical utility and commercial opportunity Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) ("Verona Pharma"), a biopharmaceutical company focused on respiratory diseases, announces the initiation of a Phase 2...

-  SRK-015 was well-tolerated in healthy volunteers across all tested doses, supporting evaluation in the ongoing Phase 2 TOPAZ trial in Spinal Muscular Atrophy (SMA) -  Pharmacodynamic results from the completed multiple-ascending dose portion of the trial show...

ARQ-151 Potential "Best in Class" Topical PDE4 inhibitor ARQ-151 is 50- to 300-fold more potent than approved PDE4 inhibitors Phase 2a Topline Data Anticipated Year End 2019 Westlake Village, CA, June 3, 2019 – Arcutis, Inc., a privately held immuno-dermatology drug...

NantKwest Inc. (Nasdaq:NK), a pioneering, next generation, clinical-stage immunotherapy company focused on harnessing the unique power of our immune system using natural killer (NK) cells to treat cancer, infectious diseases and other diseases, today announced that...

- Incyte (Nasdaq:INCY) today announced that the first patient has been treated in FIGHT-302, an open-label Phase 3 study evaluating pemigatinib (INCB54828), its selective fibroblast growth factor receptor (FGFR) inhibitor, compared to gemcitabine with cisplatin...

Large trials that go unreported threaten the credibility of available, published evidence and are detrimental to the scientific process, according to a brief research report and an editorial published in Annals of Internal Medicine. Researchers identified the 500...

French agency (ANSM) first to approve clinical trial with ABX464 in moderate to severe rheumatoid arthritis Trial to be conducted in 60 patients in five countries, with “first patient in” scheduled for early Q3 2019 Rheumatoid arthritis is a severe, debilitating...

Chinese authorities have greenlighted the clinical trial for the world's first tetravalent vaccine against norovirus, the most common cause for viral gastroenteritis. The vaccine received the clinical research permit from the National Medical Products Administration...

ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman's reproductive health and pregnancy, today reported completion of...

– Georgetown University Medical Center announces the launch of the only known therapeutic (disease modifying) clinical trial for Lewy body dementia, a neurological disorder that affects a million people in the United States for which there are no approved medications...

National Cancer Institute (NCI) Study Designed to Investigate Zotiraciclib in Combination with Temozolomide (TMZ) Presented During Poster Session at ASCO 2019 Maximum Tolerated Dose of Zotiraciclib (250mg) Elicits Tumor Reduction, Suggesting Activity in Glioblastoma...

HOLON, Israel, June 3, 2019 /PRNewswire/ -- Compugen Ltd. (CGEN), a clinical-stage cancer immunotherapy company and leader in predictive target discovery, today announced that its ongoing Phase 1 clinical trial evaluating COM701, a first-in-class therapeutic antibody...

New Clinical Data Presented Today Included in Recently Submitted NDA to FDA Epizyme, Inc. (EPZM), a late-stage biopharmaceutical company developing novel epigenetic therapies, today reported updated data on tazemetostat from the epithelioid sarcoma cohort of its...

A presentation at the ASCO Annual Meeting (June 2, 2019; Chicago, IL) explored the role that the clinical pathways program at the Levine Cancer Institute (Charlotte, NC) plays in clinical trial enrollment. Researchers from Levine Cancer Institute said that clinical...

Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today presented topline results from the pivotal European Phase 3 ARTEMIS clinical trial, which it previously announced had met its...